Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma ...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update. Strengthened Cash, Strategic Refocus and Pipeline Progress De ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...